MIRO Miromatrix Medical Inc.

Miromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company also develops organ-derived biological products for various applications, such as soft tissue reinforcement and wound care. It uses its perfusion decellularization/recellularization technology to engineer transplantable organs for the people who need them. Miromatrix Medical Inc. has strategical partnerships with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. Miromatrix Medical Inc. was formerly known as TayTech, Inc. The company was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/24/2021
Outstanding shares:  20,254,645
Average volume:  11,015
Market cap:   $140,972,329
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    60471P108
ISIN:        US60471P1084
Valuation   (See tab for details)
PE ratio:   -14.65
PB ratio:   2.27
PS ratio:   0.00
Return on equity:   -8.82%
Net income %:   -17,171.49%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy